CVTX completes Phase III CVT-510 enrollment

CV Therapeutics (CVTX) completed enrollment in a Phase III trial of tecadenoson (CVT-510) to treat paroxysmal supraventricular tachycardia (PSVT), which is an abnormally rapid heart rhythm. Endpoints ...